Commentary: Targeting NMDA Receptor and Serotonin Transporter for the Treatment of Comorbid Alcohol Dependence and Depression

评论:靶向NMDA受体和5-羟色胺转运蛋白治疗合并酒精依赖和抑郁症

阅读:1

Abstract

This commentary addresses some of the important outcomes of the published study by Ho and colleagues, titled “Combined effects of acamprosate and escitalopram on ethanol consumption in mice”, published in Alcohol Clin Exp Res. 2016 Jul;40(7):1531–1539. Ho and colleagues reported that the combination of acamprosate and escitalopram was able to reduce ethanol intake in both stressed and non-stressed mice during treatment. However, escitalopram alone reduced ethanol intake only in non-stressed mice. Acamprosate treatment did not induce any changes in ethanol intake. This commentary addresses the important roles of glutamatergic and serotonergic systems in ethanol intake and dependence. The differential effects of combined drugs or a drug administered alone on ethanol intake have been addressed with a focus on stressed versus non-stressed mice exposed to two-bottle choice limited-access drinking of 15% ethanol and tap water. The interactive role of glutamate and serotonin in ethanol intake is also discussed in this commentary.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。